Literature DB >> 15177457

Synthesis and biological activity of some known and putative duloxetine metabolites.

F Kuo1, T A Gillespie, P Kulanthaivel, R J Lantz, T W Ma, D L Nelson, P G Threlkeld, W J Wheeler, P Yi, M Zmijewski.   

Abstract

Several putative phase I duloxetine metabolites, 4-hydroxy-, 5-hydroxy-, 6-hydroxy-, 5-hydroxy-6-methoxy-, 6-hydroxy-5-methoxy-, 5,6-dihydroxy-, and 4,6-dihydroxyduloxetine were synthesized, and their phase II metabolite as glucuronide or sulfate conjugates were also synthesized. Their in vitro binding activities were compared to that of parent compound duloxetine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15177457     DOI: 10.1016/j.bmcl.2004.04.066

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2014-03

2.  Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.

Authors:  Evelyn D Lobo; Michael Heathman; Han-Yi Kuan; Shobha Reddy; Lisa O'Brien; Celedon Gonzales; Michael Skinner; Mary Pat Knadler
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

Review 3.  Duloxetine: clinical pharmacokinetics and drug interactions.

Authors:  Mary Pat Knadler; Evelyn Lobo; Jill Chappell; Richard Bergstrom
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

4.  Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.

Authors:  Si Tianmei; Mary Pat Knadler; Ming T Lim; Kwee Poo Yeo; Leyan Teng; Shu Liang; Alan X Pan; Evelyn D Lobo
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 5.  Duloxetine: a review of its use in the treatment of major depressive disorder.

Authors:  James E Frampton; Greg L Plosker
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 6.  Antipsychotic treatment modulates glutamate transport and NMDA receptor expression.

Authors:  Mathias Zink; Susanne Englisch; Andrea Schmitt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-12       Impact factor: 5.270

7.  Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups.

Authors:  Bernardo Dell'osso; Giulia Camuri; Cristina Dobrea; Massimiliano Buoli; Marta Serati; A Carlo Altamura
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-11-02

8.  Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice.

Authors:  Marco Redaelli; María Jimena Ricatti; Marialaura Simonetto; Mirko Claus; Maurizio Ballabio; Antonio Caretta; Carla Mucignat-Caretta
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 9.  Review of duloxetine in the management of diabetic peripheral neuropathic pain.

Authors:  Timothy Smith; Robert A Nicholson
Journal:  Vasc Health Risk Manag       Date:  2007

10.  Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States.

Authors:  Kristin Palmsten; Sonia Hernández-Díaz; Krista F Huybrechts; Paige L Williams; Karin B Michels; Eric D Achtyes; Helen Mogun; Soko Setoguchi
Journal:  BMJ       Date:  2013-08-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.